@article{JTD25268,
author = {Dragana Jovanovic and Marina Roksandic Milenkovic and Jelena Kotur Stevuljevic and Jelena Markovic and Vesna Ceriman and Milica Kontic and Vesna Skodric Trifunovic},
title = {Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis—a pilot study},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {12},
year = {2018},
keywords = {},
abstract = {Background: Idiopathic pulmonary fibrosis (IPF) has common risk factors with cancer and significant similarities in the pathobiology process, both diseases having poor outcomes. Immune checkpoint PD-L1 has become the target of checkpoint inhibitory therapy that unleashes antitumor T cells and has revolutionized cancer treatment. This is a pilot study exploring membrane immune checkpoint PD-L1 expression in human IPF lung tissue samples and its soluble form, soluble PD-L1 (sPD-L1) plasma concentrations in IPF patients, in order to investigate potential role of PD-L1 as an IPF biomarker.
Methods: Twelve human IPF lung tissue samples (formalin-fixed, paraffin-embedded) obtained by surgical biopsy, have been tested for PD-L1 expression by PD-L1 IHC 22C3 pharmDx assay, while plasma samples for examination of sPD-L1 forms, PD-L1 (B7-H1/CD274) blood concentration, originated from 23 patients with IPF who did not undergo surgical biopsy.
Results: Membrane PD-L1 expression in IPF lung tissue samples was positive to overexpression of PD-L1 in 9 samples out of 12. Only very few cells in the interstitium have shown a discrete PD-L1 expression, but not of a membrane type. As for sPD-L1 forms, we have found elevated concentrations of sPD-L1 in the serum of IPF patients 314.3 ng/L (117.7–483.1 ng/L), significantly higher compared with healthy control group 91.0 ng/L (52.4–119.7 ng/L), P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/25268}
}